Bone Biologics Corporation (BBLGW) Net income 2016–2025
Bone Biologics Corporation (BBLGW) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$3.1MFY2025 · since FY2016: -$25.9M → -$3.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$3.1M | +24.4% |
| FY2024 | -$4.1M | +54.0% |
| FY2023 | -$8.9M | -502.8% |
| FY2022 | -$1.5M | +7.8% |
| FY2021 | -$1.6M | +11.7% |
| FY2020 | -$1.8M | +46.7% |
| FY2019 | -$3.4M | +22.7% |
| FY2018 | -$4.4M | +37.2% |
| FY2017 | -$7.1M | +72.8% |
| FY2016 | -$25.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BBLGW financial trends
BBLGW RevenueBBLGW Net marginBBLGW Gross profitBBLGW Gross marginBBLGW Operating incomeBBLGW Operating marginBBLGW Operating cash flowBBLGW Free cash flowBBLGW Capital expendituresBBLGW Return on equityBBLGW Stock buybacksBBLGW Dividends paidBBLGW Total assetsBBLGW Total liabilitiesBBLGW Shareholders’ equityBBLGW overview →